Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
CD27; S152; T14; Tp55; CD27L receptor;
(Note: Up to 8-plex in one testing reaction)
- Product No.ULMB043Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Download Instruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
-
FOB
US$ 207
For more details, please contact local distributors! US$ 215
For more details, please contact local distributors! US$ 227
For more details, please contact local distributors! US$ 243
For more details, please contact local distributors! US$ 259
For more details, please contact local distributors! US$ 283
For more details, please contact local distributors! US$ 319
For more details, please contact local distributors!US$ 399
For more details, please contact local distributors!
-
Packages (Simulation)
-
Packages (Simulation)
-
ISO9001: 2008, ISO13485: 2003 Registered
Specificity of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
This assay has high sensitivity and excellent specificity for detection of Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
Matrices listed below were spiked with certain level of recombinant Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-92 | 86 |
| EDTA plasma(n=5) | 98-105 | 102 |
| heparin plasma(n=5) | 78-101 | 84 |
Precision of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 90-97% | 80-103% | 98-105% | 89-98% |
| EDTA plasma(n=5) | 88-95% | 93-105% | 79-89% | 89-101% |
| heparin plasma(n=5) | 80-104% | 93-103% | 83-101% | 91-98% |
Stability of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Assay procedure summary of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle of the Multiplex Assay Kit for Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7) ,etc. by FLIA (Flow Luminescence Immunoassay)
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
GIVEAWAYS